Monopar Therapeutics is a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. Monopar's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients; camsirubicin for the treatment of advanced soft tissue sarcoma; and a late-stagepreclinical antibody, MNPR-101, for advanced cancers and severe COVID-19.
Company profile
Ticker
MNPR
Exchange
Website
CEO
Chandler Drew Robinson
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Monopar Therapeutics Australia Ltd • Monopar Therapeutics, SARL ...
IRS number
320463781
MNPR stock data
Analyst ratings and price targets
Current price
Average target
$21.00
Low target
$18.00
High target
$24.00
EF Hutton
Initiated
$24.00
Roth Capital
Maintains
$18.00
Latest filings (excl ownership)
8-K
Monopar Announces Projected Timeline of Upcoming Q1 2023 Data
26 Jan 23
8-K
Monopar Announces Successful Advancement of Camsirubicin Phase 1b Clinical Trial Past Fourth Cohort, Escalates Next to 650mg/m2
18 Jan 23
EFFECT
Notice of effectiveness
5 Jan 23
424B5
Prospectus supplement for primary offering
4 Jan 23
CORRESP
Correspondence with SEC
29 Dec 22
UPLOAD
Letter from SEC
28 Dec 22
S-3
Shelf registration
21 Dec 22
8-K
Monopar Announces Promising MNPR-202 Data
12 Dec 22
8-K
Monopar Announces Encouraging Clinical Data
16 Nov 22
10-Q
2022 Q3
Quarterly report
10 Nov 22
Latest ownership filings
Financial summary
| Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 14.32 mm | 14.32 mm | 14.32 mm | 14.32 mm | 14.32 mm | 14.32 mm |
| Cash burn (monthly) | 715.70 k | 668.76 k | 802.45 k | 859.08 k | 716.16 k | (no burn) |
| Cash used (since last report) | 3.09 mm | 2.89 mm | 3.47 mm | 3.71 mm | 3.10 mm | n/a |
| Cash remaining | 11.22 mm | 11.43 mm | 10.85 mm | 10.60 mm | 11.22 mm | n/a |
| Runway (months of cash) | 15.7 | 17.1 | 13.5 | 12.3 | 15.7 | n/a |
Institutional ownership, Q2 2022
1.6% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 12 |
| Opened positions | 2 |
| Closed positions | 2 |
| Increased positions | 2 |
| Reduced positions | 4 |
| 13F shares | Current |
|---|---|
| Total value | 482.00 k |
| Total shares | 207.34 k |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Vanguard | 99.88 k | $230.00 k |
| Geode Capital Management | 39.17 k | $85.00 k |
| NTRS Northern Trust | 35.20 k | $81.00 k |
| UBS UBS Group AG - Registered Shares | 19.56 k | $45.00 k |
| RY Royal Bank Of Canada | 4.12 k | $9.00 k |
| MS Morgan Stanley | 4.00 k | $9.00 k |
| Tower Research Capital | 2.37 k | $5.00 k |
| BLK Blackrock | 2.33 k | $5.00 k |
| IFP Advisors | 500.00 | $13.00 k |
| Captrust Financial Advisors | 170.00 | $0.00 |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 Feb 23 | Starr Christopher M | RSU Common Stock | Grant | Acquire A | No | No | 0 | 10,133 | 0.00 | 10,133 |
| 1 Feb 23 | Starr Christopher M | Stock Options Common Stock | Grant | Acquire A | No | No | 3.16 | 13,930 | 44.02 k | 13,930 |
| 1 Feb 23 | Andrew Cittadine | RSU Common Stock | Grant | Acquire A | No | No | 0 | 78,234 | 0.00 | 126,984 |
| 1 Feb 23 | Andrew Cittadine | Stock Options Common Stock | Grant | Acquire A | No | No | 3.16 | 102,688 | 324.49 k | 102,688 |
| 1 Feb 23 | Kim R Tsuchimoto | RSU Common Stock | Grant | Acquire A | No | No | 0 | 78,234 | 0.00 | 135,382 |
| 1 Feb 23 | Kim R Tsuchimoto | Stock Options Common Stock | Grant | Acquire A | No | No | 3.16 | 102,688 | 324.49 k | 102,688 |
| 1 Feb 23 | Klausner Arthur J | RSU Common Stock | Grant | Acquire A | No | No | 0 | 10,133 | 0.00 | 10,133 |
| 1 Feb 23 | Klausner Arthur J | Stock Options Common Stock | Grant | Acquire A | No | No | 3.16 | 13,930 | 44.02 k | 13,930 |
| 1 Feb 23 | Chandler Robinson | RSU Common Stock | Grant | Acquire A | No | No | 0 | 169,012 | 0.00 | 326,907 |
| 1 Feb 23 | Chandler Robinson | Stock Options Common Stock | Grant | Acquire A | No | No | 3.16 | 221,839 | 701.01 k | 221,839 |
News
Benzinga's Top Ratings Upgrades, Downgrades For January 23, 2023
23 Jan 23
EF Hutton Initiates Coverage On Monopar Therapeutics with Buy Rating, Announces Price Target of $24
23 Jan 23
12 Health Care Stocks Moving In Friday's Pre-Market Session
20 Jan 23
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
20 Dec 22
12 Health Care Stocks Moving In Friday's Pre-Market Session
16 Dec 22